Cargando…
Pharmacodynamic and pharmacokinetic properties of the combined preparation of levothyroxine plus sustained- release liothyronine; a randomized controlled clinical trial
BACKGROUND: Understanding pharmacokinetics (PK) and pharmacodynamics (PD) of the sustained-release liothyronine (SR-T3) is of paramount importance to design therapeutic regimens that are able to simulate normal thyroid hormone secretion while avoiding excursions in the T3 serum concentration. Here,...
Autores principales: | Mehran, Ladan, Amouzegar, Atieh, Foroutan, Seyed Mohsen, Masoumi, Safdar, Tohidi, Maryam, Abdi, Hengameh, Aghaei, Ali, Saghafinia, Amir Esmaeel, Azizi, Fereidoun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463362/ https://www.ncbi.nlm.nih.gov/pubmed/37641049 http://dx.doi.org/10.1186/s12902-023-01434-y |
Ejemplares similares
-
LT4 and Slow Release T3 Combination: Optimum Therapy for Hypothyroidism?
por: Azizi, Fereidoun, et al.
Publicado: (2020) -
Tehran Thyroid Study (TTS)
por: Amouzegar, Atieh, et al.
Publicado: (2018) -
Blood Pressure and Hypertension: Findings from 20 Years of the Tehran Lipid and Glucose Study (TLGS)
por: Abdi, Hengameh, et al.
Publicado: (2018) -
Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study
por: Honarvar, Mohammadjavad, et al.
Publicado: (2023) -
Trajectory patterns of metabolic syndrome severity score and risk of type 2 diabetes
por: Amouzegar, Atieh, et al.
Publicado: (2023)